| Issue Date | Title | Author(s) |
| 2018 | Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma | Jin, Jie; Okamoto, Rumiko; Yoon, Sung-Soo; Shih, Lee-Yung; Zhu, Jun; Liu, Ting; Hong, Xiaonan; Pei, Lixia; Rooney, Brendan; van de Velde, Helgi; Huang, Huiqiang |
| 2017 | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China | Shi, Yuankai; Jia, Bo; Xu, Wei; Li, Wenyu; Liu, Ting; Liu, Peng; Zhao, Weili; Zhang, Huilai; Sun, Xiuhua; Yang, Haiyan; Zhang, Xi; Jin, Jie; Jin, Zhengming; Li, Zhiming; Qiu, Lugui; Dong, Mei; Huang, Xiaobing; Luo, Yi; Wang, Xiaodong; Wang, Xin; Wu, Jianqiu; Xu, Jingyan; Yi, Pingyong; Zhou, Jianfeng; He, Hongming; Liu, Lin; Shen, Jianzhen; Tang, Xiaoqiong; Wang, Jinghua; Yang, Jianmin; Zeng, Qingshu; Zhang, Zhihui; Cai, Zhen; Chen, Xiequn; Ding, Kaiyang; Hou, Ming; Huang, Huiqiang; Li, Xiaoling; Liang, Rong; Liu, Qifa; Song, Yuqin; Su, Hang; Gao, Y |
| 16-Oct-2023 | Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies | Song, Yuqin; Wu, Shang-Ju; Shen, Zhixiang; Zhao, Donglu; Chan, Thomas Sau Yan; Huang, Huiqiang; Qiu, Lugui; Li, Jianyong; Tan, Tran-der; Zhu, Jun; Song, Yongping; Huang, Wei-Han; Zhao, Weili; Liu, Herman Sung Yu; Xu, Wei; Chen, Naizhi; Ma, Jun; Chang, Cheng-Shyong; Tse, Eric Wai Choi |
| 2019 | Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 | Lin, Yansong; Huang, Huiqiang; Guo, Ye; Chen, Libo; Bao, Jiandong; Chen, Ge; Chen, Libo; Cui, Yali; Ding, Yong; Guan, Haixia; Guo, Ye; Gao, Zairong; Huang, Huiqiang; Huang, Rui; Huang, Tao; Hou, Xiaorong; He, Xiayun; Li, Mei; Li, Shaohua; Li, Xiaoyi; Li, Xuena; Li, Yujun; Liang, Zhiyong; Luo, Yukun; Lin, Yansong; Lyu, Jing; Ma, Qingjie; Niu, Lijuan; Sun, Wenhai; Wang, Feng; Wang, Renfei; Wei, Feng; Xia, Yu; Yang, Aiming; Zhang, Bin; Zhang, Bo; Zhang, Guang; Zhang, Hong; Zhang, Li; Zheng, Xiangqian; An, Rui; Fang, Jugao; Fan, Youben; Gao, Ming; Guo, Zhuming; Huang, Gang; Ji, Qinghai; Jiang, Ningyi; Jiang, Yuxin; Kuang, Anren; Li, Fang; Li, Sijin; Li, Yaming; Liu, Shaoyan; Sun, Hui; Shan, Zhongyan; Tan, Jian; Tian, Wen; Wang, Jing; Wang, Tie; Xing, Xiaoping; Xu, Zhengang; Zhang, Fuquan; Zhao, Jiajun; Zhao, Yupei; Zhu, Jingqiang; Li, Hui; Li, Jiao; Li, Li; Zhang, Yingjie; Zhao, Teng |
| 15-Feb-2021 | Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study | Huang, Huiqiang; Zhu, Jun; Yao, Ming; Kim, Tae Min; Yoon, Dok Hyun; Cho, Seok-Goo; Eom, Hyeon Seok; Lim, Soon Thye; Yeh, Su-peng; Song, Yuqin; Kwong, Yok Lam; Kim, Jin Seok; Jin, Jie; Shi, Yuankai; Kim, HyeJin; Qing, Min; Zhou, Tianyuan; Gao, Grace; Dong, Zongqi; Qi, Ming; Kim, Won Seog |
| 4-Nov-2021 | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China | Liu, Weiping; Zhao, Donglu; Liu, Ting; Niu, Ting; Song, Yongping; Xu, Wei; Jin, Jie; Cai, Qingqing; Huang, Huiqiang; Li, Zhiming; Hou, Ming; Zhang, Huilai; Zhou, Jianfeng; Hu, Jianda; Shen, Jianzhen; Shi, Yuankai; Yang, Yu; Zhang, Liling; Zhao, Weili; Ding, Kaiyang; Qiu, Lugui; Tan, Huo; Zhang, Zhihui; Liu, Lihong; Wang, Jinghua; Xu, Bing; Zhou, Hui; Gao, Guangxun; Xue, Hongwei; Bai, Ou; Feng, Ru; Huang, Xiaobing; Yang, Haiyan; Yan, Xiaojing; Zeng, Qingshu; Liu, Peng; Li, Wenyu; Mao, Min; Su, Hang; Wang, Xin; Xu, Jingyan; Zhou, Daobin; Zhang, Hongyu; Ma, Jun; Shen, Zhixiang; Zhu, Jun |
| 2015 | Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | Shi, Yuankai; Dong, Mei; Zhu, Jun; Zhou, Daobin; Huang, Huiqiang; Tu, Ping; Zhang, Weijing; Hong, Xiaonan; Zhao, Xielan; Sun, Jianfang; Liu, Yuehua; Qiu, Lugui; Shen, ZhiXiang; Feng, Jifeng; Ke, Xiaoyan |
| 2015 | Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | Shi, Yuankai; Dong, Mei; Zhu, Jun; Zhou, Daobin; Huang, Huiqiang; Tu, Ping; Zhang, Weijing; Hong, Xiaonan; Zhao, Xielan; Sun, Jianfang; Liu, Yuehua; Qiu, Lugui; Shen, ZhiXiang; Feng, Jifeng; Ke, Xiaoyan |
| 2018 | Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study | Zhu, Jun; Huang, Huiqiang; Chen, Huan; Zhang, Xi; Li, Zengjun; Wu, Depei; Zhou, Daobin; Song, Yongping; Hu, Yu; Liang, Yingmin; Ren, Hanyun; Huang, He; Li, Nainong; Chen, Hu; Hu, Jiong; Li, Jianyong; Meng, Robin; Wu, Junlong; Yu, Dong; Huang, Xiaojun |
| 2019 | Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study | Hong, Xiaonan; Song, Yuqin; Huang, Huiqiang; Bai, Bing; Zhang, Huilai; Ke, Xiaoyan; Shi, Yuankai; Zhu, Jun; Lu, Guodong; Liebscher, Stefan; Cai, Chunxiao |
| 15-Nov-2022 | XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma:Updates of the Phase Ib Touch Study | Huang, Huiqiang; Gao, Yan; Zhang, Huilai; Zhou, Keshu; Wu, Jianqiu; Cai, Zhen; Jing, Hongmei; Fan, Lei; Lou, Sai; Fei, Yizhou; Wang, Aihua; Lynch, Kevin |
